Semax in Neuropeptide Research requires traceable specification (5mg / 10mg) and RUO acknowledgment; Semax Specification and Vial Format Review outlines buyer steps on sulanpeptide.vip.
Semax is a synthetic ACTH-derived heptapeptide used in laboratory research on neuropeptide signaling, melanocortin-related pathway models, peptide stability, and cellular response studies.
Semax is an ACTH(4-10) analog studied for neurotrophic effects involving BDNF upregulation and dopaminergic pathway modulation in stroke and hypoxia rodent models. Heptapeptide lacks corticotropic activity of full ACTH while retaining CNS signaling properties in blood–brain barrier penetration research.
Morris water maze performance, infarct volume histology (TTC staining), and BDNF ELISA from brain homogenates are recurring experimental endpoints. Institute of Molecular Genetics ( Moscow ) publications established Semax in cerebral ischemia research models as a neuroactive peptide probe.
Principal investigators should sign off Semax SKUs only after mechanism fit is documented in the study protocol. Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Side-by-side review of specification table, vial label, and COA prevents release errors for Semax.
Catalog identifiers for Semax: CAS 80714-61-0, Formula: C37H51N9O10S. MW 813.9 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for Semax to support reproducibility.
Dose planning for Semax should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Specification alignment for Semax requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for Semax—CAS 80714-61-0, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Semax should include these fields for reproducibility in Neuropeptide Research journals.
Format selection for Semax affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Semax. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Semax should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Semax. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Semax should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
Format selection for Semax affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Semax from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.